Leap Therapeutics

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Albireo Pharma

Evoqua Water Technologies

Concert Pharma

NEW YORK , Jan. 30, 2023 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. Weiss Law 305 Broadway, 7th Floor  New York, NY 10007 (212) 682-3025  (888) 593-4771 stockinfo@weisslawllp.com Evoqua Water Technologies Corp. (NYSE: AQUA) Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Evoqua Water Technologies Corp. (NYSE: AQUA) in connection with the proposed acquisition of AQUA by Xylem Inc. ("Xylem").

SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations

AstraZeneca

BioNTech SE

CVS Health

Gilead Sciences

LHC Group

Moderna

Neovasc

Signify Health

Sanofi

Shockwave Medical

UnitedHealth Group

Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $6 billion sale of LHC Group Inc. (Nasdaq: LHCG) to UnitedHealth (NYSE: UNH) and the $8 billion sale of Signify Health Inc. (NYSE: SGFY) to CVS Health Co. (NYSE: CVS).

Mergers and Acquisitions in 2023 Off To A Strong Start

NEW YORK--( BUSINESS WIRE )--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Leap Therapeutics, Inc. (NASDAQ: LPTX) and Flame Biosciences, Inc. is fair to Leap shareholders. Under the terms of the merger agreement, Leap will issue approximately 19,794,373 shares of its common stock and approximately 136,833 shares of a newly designated Series X non-voting convertible preferred stock to Flame stockholders.

LPTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Leap Therapeutics, Inc. Is Fair to Shareholders

Wilmington, Delaware--(Newsfile Corp. - January 19, 2023) - Rigrodsky Law, P.A. is investigating Leap Therapeutics, Inc. ("Leap") (NASDAQ: LPTX) regarding possible breaches of fiduciary duties and other violations of law related to Leap's agreement to be acquired by Flame Biosciences, Inc.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-leap-therapeutics-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Leap Therapeutics, Inc. Buyout

NEW YORK , Jan. 18, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Leap Therapeutics, Inc. (NASDAQ: LPTX), relating to its proposed purchase of Flame Biosciences, Inc. Under the terms of the agreement, LPTX will issue shares of common stock and Series X non-voting convertible preferred stock to Flame shareholders, with each Series X share convert to 1000 shares of common stock upon approval of the transaction. Click here for more information: https://www.monteverdelaw.com/case/leap-therapeutics-inc.

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Leap Therapeutics, Inc. - LPTX

NEW YORK , Jan. 18, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Leap Therapeutics, Inc. ("Leap" or the "Company") (NASDAQ: LPTX), in connection with the proposed purchase of Flame Biosciences, Inc. ("Flame"). Under the terms of the merger agreement, the Company will issue approximately 19,794,373 shares of its common stock and approximately 136,833 shares of a newly designated Series X non-voting convertible preferred stock to Flame shareholders.

SHAREHOLDER ALERT: Weiss Law Investigates Leap Therapeutics, Inc.

Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap's pipeline Combined cash balance of approximately $115 million enhances runway to mid-2025, fully-funding advancement of DKN-01 and FL-301 Leap to host conference call at 9:00 a.m. ET today CAMBRIDGE, Mass.

Leap Therapeutics Acquires Flame Biosciences

CAMBRIDGE, Mass. , Jan. 11, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.

Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference

CAMBRIDGE, Mass. , Nov. 21, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.

Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference

CAMBRIDGE, Mass. , Nov. 14, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2022.

Leap Therapeutics Reports Third Quarter 2022 Financial Results

55% ORR, 73% DCR, and 7.7 month PFS in DKK1-high/PD-L1-high second-line gastric cancer patients DKN-01 also demonstrated preclinical tumor regression data in CRC models supporting ongoing clinical trial CAMBRIDGE, Mass. , Nov. 7, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from Part B of the DisTinGuish study evaluating DKN-01 in combination with tislelizumab, BeiGene's anti-PD-1 antibody, in second-line gastroesophageal adenocarcinoma (GEA) cancer patients whose tumors express high levels of DKK1 (DKK1-high) at the Society of Immunotherapy for Cancer (SITC) 37th Annual Meeting being held in Boston, MA on November 8-12, 2022.

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

CAMBRIDGE, Mass. , Oct. 17, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced that the first patient has been enrolled in the Phase 2 DeFianCe study evaluating DKN-01, Leap's anti-Dickkopf-1 antibody (DKK1), in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanced colorectal cancer (CRC).

Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

CAMBRIDGE, Mass. , Oct. 12, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the first patient has been enrolled in the randomized controlled Part C of the ongoing DisTinGuish study to evaluate DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy compared to a tislelizumab and chemotherapy control arm, in patients with gastric or gastroesophageal junction cancer (G/GEJ).

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

CAMBRIDGE, Mass. , Sept. 7, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.

Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference

CAMBRIDGE, Mass. , Sept. 6, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the appointment of Richard L.

Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with DKN-01 plus tislelizumab and CAPOX, exceeding benchmarks in the overall population and in DKK1 and PD-L1 subgroups Median Overall Survival is not mature with only 44% of patients deceased as of the data cut Enrollment ongoing in the study of DKN-01 plus Tecentriq® (atezolizumab) in second- or third-line oesophagogastric cancer patients, activity in DKK1-high patients consistent with prior studies with pembrolizumab or tislelizumab CAMBRIDGE, Mass. , Sept. 4, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting data in first-line patients with advanced gastroesophageal adenocarcinoma (GEA) from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy, at the European Society for Medical Oncology (ESMO) Congress 2022 being held on September 9-12.

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress

CAMBRIDGE, Mass. , Aug. 12, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2022.

Leap Therapeutics Reports Second Quarter 2022 Financial Results

Dr. Bertagnolli to Transition Off Leap's Board of Directors CAMBRIDGE, Mass. , Aug. 12, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics today announced that its Board member, Monica Bertagnolli, MD, has been appointed as the 16th Director of the National Cancer Institute (NCI) by the Biden administration.

Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute

BeiGene

Randomized Controlled First-Line Gastric Cancer Trial of DKN-01 plus tislelizumab and chemotherapy in collaboration with BeiGene Leap to host R&D Day today at 12:00 p.m. ET CAMBRIDGE, Mass.

Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer

Boot Barn Hlds

Canada Goose Holdings

MEDNAX

Oncolytics Biotech, Inc.

Want to try an out-of-the-box approach? Tap Oncolytics Biotech (ONCY), Pediatrix Medical Group Inc (MD), Boot Barn (BOOT), Canada Goose (GOOS) and Leap Therapeutics (LPTX).

Ride on Rising P/E Investing With These 5 Top-Ranked Stocks

Positive results using DKN-01 plus chemotherapy for the treatment of patients with metastatic castration-resistant prostate cancer were presented at ASCO 2022 medical conference. The global prostate cancer market could reach $12 billion by 2025.

Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022

CAMBRIDGE, Mass. , June 27, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will host a virtual R&D Day on July 12, 2022 at 12:00 pm ET.

Leap Therapeutics to Host Virtual R&D Day on July 12, 2022

CAMBRIDGE, Mass. , May 26, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that initial clinical data from the investigator-sponsored Phase 1b/2a dose escalation and dose expansion study testing Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, as monotherapy or in combination with docetaxel in metastatic castration-resistant prostate cancer (mCRPC) will be presented at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL on June 3-7, 2022.

Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting

CAMBRIDGE, Mass. , May 13, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2022.

Leap Therapeutics Reports First Quarter 2022 Financial Results

Baosheng Media Group Holdings

Medavail Holdings Inc

Check these three penny stocks out for your watchlist right now The post Check These 3 Penny Stocks Out For Your Watchlist Right in Late-April  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check These 3 Penny Stocks Out For Your Watchlist Right in Late-April

News for Leap Therapeutics Stock (LPTX)